Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Condition(s):Graft vs Host DiseaseLast Updated:May 15, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Graft vs Host DiseaseLast Updated:May 15, 2023Completed
Condition(s):Type 1 DiabetesLast Updated:March 13, 2017Completed
Condition(s):Metabolism Disorder, Lipid; Metabolism Disorder, GlucoseLast Updated:February 14, 2022Unknown status
Condition(s):Coronary Artery DiseaseLast Updated:April 12, 2023Completed
Condition(s):HealthyLast Updated:April 3, 2012Completed
Condition(s):Leukemia; Lymphoma, Non-HodgkinLast Updated:December 2, 2017Completed
Condition(s):Stable Coronary Artery DiseaseLast Updated:August 31, 2021Terminated
Condition(s):HypercholesterolemiaLast Updated:February 17, 2022Completed
Condition(s):IschemiaLast Updated:March 22, 2017Completed
Condition(s):Myotoxicity of Atorvastatin TreatmentLast Updated:December 3, 2014Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.